Company intelligence / Profile preview

Revidia Therapeutics

Lamoine, ME, USrevidiatherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Revidia Therapeutics is a preclinical stage biotech company focused on developing small molecule therapeutics for cardiac repair and regeneration through PTP1B inhibition.

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

MSI-1436

IND

Indications: Heart failure, Duchenne muscular dystrophy cardiomyopathy

Partnerships

{"type":"Grant funding","partner":"National Heart, Lung, and Blood Institute"}

Beyond the preview

Go deeper on Revidia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revidia Therapeutics.

Explore the full profile